ArticleApplied biochemistry and biotechnology2025
Relationship Between Activating Transcription Factor 3 and Forkhead Box Protein A2 in Spinal Cord Injury and the Underlying Mechanism.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Activating transcription factor 3 (ATF3) may function as a regulator of various diseases; however, its role in spinal cord injury (SCI) remains unknown. We designed a current work to evaluate the potentials of the ATF3/forkhead box protein A2 (FOXA2) axis in SCI. GSE45006 chip was analyzed, and a volcano plot and heatmap were drawn. Gene Ontology and KEGG analysis were performed for the differentially expressed genes. Animals with SCI were established. Quantitative reverse transcription polymerase chain reaction and western blotting were used to determine mRNA expression, and western blotting was used for detecting protein expression. The interaction between FOXA2 and the ATF3 promoter was evaluated using the UCSC database and confirmed using dual-luciferase and chromatin immunoprecipitation assays. Cellular behaviors were determined using CCK-8, EdU, and TUNEL assays. Levels of p-PI3K, PI3K, p-AKT, and AKT were examined by the WB method. We found that ATF3 expression was markedly increased in rats with SCI. Interestingly, ATF3 knockdown increased the proliferation and suppressed the apoptotic ability of PC12 cells. FOXA2 activates ATF3 transcription. Knockdown of FOXA2-mediated down-regulation of ATF3 increases growth and decreases PC12 cell death. ATF3 knockdown could increase the level of p-PI3K and p-AKT; FOXA2 shRNA could affect the expression of p-PI3K and p-AKT, which was partially abrogated by ATF3 OE. Forkhead box protein regulates the transcription of ATF3, thereby affecting cell growth and PC12 cell death.
Indexed as
Identifiers
40464835What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.